Sacituzumab Govitecan Benefits in HR+/HER2- Breast Cancer

ASCENT-07 Study Summary: Sacituzumab Govitecan vs. Chemotherapy in Breast Cancer

HereS a summary of the ASCENT-07 ⁣study based on the⁢ provided text:

Study Design:

* Participants: 690‍ adults with HR+/HER2−,⁢ locally advanced unresectable or metastatic breast ⁢cancer.
* Treatment: Participants were randomly assigned to receive either:
⁤* Sacituzumab ​Govitecan (SG) 10 mg/kg intravenously
* Chemotherapy of physician’s choice (TPC) – capecitabine, nab-paclitaxel, or paclitaxel.
*‍ Stratification: Randomization⁤ considered prior CDK4/6 inhibitor use, HER2 immunohistochemistry status, adn geographic region.
* Primary Endpoint: ‌ Progression-Free Survival (PFS) assessed by⁢ blinded autonomous central review (BICR) using RECIST v1.1 criteria.
* Secondary Endpoints: Overall Survival ‍(OS),Objective ⁤Response Rate (ORR),Quality of Life,Duration of ⁢Response (DOR),and​ safety.

Key Results:

*​ patient Distribution: 456 received SG, 234 received TPC. The majority‍ of participants (92-93%) had previously received CDK4/6 inhibitors.
* ⁤ PFS:

⁤* ‍ BICR: SG did ⁢ not ⁤show a statistically​ meaningful advancement in PFS compared to TPC (HR 0.85; ​95% CI, 0.69-1.05; P* = 0.130).
* Investigator Assessment: ‌ A numerical improvement in PFS was ​observed with SG (HR 0.78; 95% ⁤CI, 0.64-0.93;‌ nominal *P = 0.008).
* ⁤ OS: Data were immature (27% maturity) but showed an early trend favoring SG (HR 0.72; ⁢95% CI, 0.54-0.97; nominal *P* = 0.029).
* ‌ ORR: Comparable between​ SG⁢ and⁣ TPC ‍(37% vs 33%).
* ⁢ DOR: Longer with SG (12.1 months) compared to TPC (9.3 months).
* Adverse‍ Events: Grade 3 or higher neutropenia was more common with SG‌ (56%) than TPC (21%).Despite this, dose reductions were similar between groups, and fewer ‌participants discontinued treatment with SG.

Conclusions:

* The study did not meet its primary endpoint of PFS ⁤by ‌BICR.
* ‍ No new safety concerns were identified.
* There was an early trend ⁤suggesting a potential OS benefit with SG.

In essence, while SG didn’t considerably improve PFS as measured⁤ by the primary⁢ endpoint,⁤ there were⁤ signals of potential benefit in other areas, particularly OS, warranting ⁤further inquiry.